Grants We Funded
Grant applicants for the 2022 cycle requested a total of over $2.9 million dollars. The PSF Study Section subcommittees of Basic & Translational Research and Clinical Research evaluated 115 grant applications on the following topics:
The PSF awarded research grants totaling almost $550,000 to support 19 plastic surgery research proposals.
ASPS/PSF leadership is committed to continuing to provide high levels of investigator-initiated research support to ensure that plastic surgeons have the needed research resources to be pioneers and innovators in advancing the practice of medicine.
Search The PSF database to have easy access to full-text grant abstracts from past PSF-funded research projects 2003 to present. All abstracts are the work of the Principal Investigators and were retrieved from their PSF grant applications. Several different filters may be applied to locate abstracts specific to a particular focus area or PSF funding mechanism.
Radiotherapy for Revasculatization and Reperfusion of an Ischemic Flap
Jamie Levine MD
New York University Medical Center
Basic Research Grant
Chronic ischemic wounds continue to frustrate surgeons because few therapies exist that induce the repair of compromised endothelium or damaged vasculature. One approach to this challenge is to stimulate vasculogenesis, where endothelial progenitor cells (EPCs) home to sites of ischemia to restore adequate tissue perfusion. While hypoxia and inflammation are known to affect EPC homing, other stimuli are important to investigate as potential therapeutic targets. One such stimulus may be radiation therapy. Although radiation has traditionally been thought to be harmful on a cellular level (e.g. oncologic therapy), recent data demonstrates that low dose radiation may stimulate neovascularization, suggesting a potential role in revascularization therapy. Therefore, we propose that low dose radiation can exert a vasculogenic effect by stimulating EPCs to home to a site of vascular ischemia. We hypothesize that radiation stimulates EPC mobilization through the stabilization of HIF-I, a protein that transcriptionally activates chemokines responsible for initiating vasculogenesis.